Senju Pharmaceutical Inactive USPTO patentsUtility application

Utility

Therapeutic Agent for COVID-19

7 Dec 23

The present invention aims to develop a method for treating COVID-19 caused by SARS-CoV-2 or a mutant strain thereof, and provides an agent for preventing and/or treating COVID-19 caused by SARS-CoV-2 or a mutant strain thereof, the agent comprising a specific compound.

Mitsuyoshi AZUMA, Chiho FUKIAGE, Takashi IMADA, Yayoi KISHIMOTO, Noriyasu HIRASAWA, Yoshiro SAITO, Takashi TOYAMA

Filed: 29 Oct 21

Utility

Corneal Endothelium Ecm Therapeutic Medicaments

5 Oct 23

The present invention provides medicaments for treating or preventing a disease, disorder, or condition associated with extracellular matrix (ECM) abnormality in a corneal endothelium, wherein the medicaments comprise a TGF-beta signal inhibiting agent.

Noriko KOIZUMI, Naoki OKUMURA, Shigeru KINOSHITA

Filed: 7 Jun 23

Utility

dwkfm24mtoqpycor4m1vsbqpcax1y5

6 Jul 23

The invention provides an agent for promoting adhesion of a corneal endothelial cell, containing a Rho kinase inhibitor, as well as a culture medium for a corneal endothelial cell, a solution for preservation of cornea, and a method of producing a corneal endothelial preparation, which includes culturing the corneal endothelial cell using the aforementioned culture medium.

Noriko KOIZUMI, Shigeru KINOSHITA, Morio UENO

Filed: 13 Mar 23

Utility

z0c6szp4lrcfz 1ufvxwj

4 May 23

Provided are a bodily fluid-collecting device that is capable of collecting a fixed amount of bodily fluid while minimizing damage to a living body, a method for collecting a bodily fluid using the device, and a method for collecting an aqueous humor using the device A bodily fluid-collecting device 1 comprises a needle part 2 having a needle tube 3 with a needle tip 32, and a capillary 5 removably connected to a base end part 33 of the needle tube 3 in its longitudinal direction on a side opposite to the needle tip 32.

Ryo YOSHINAGA, Tatsuya SAKAI

Filed: 26 Mar 21

Utility

gyl97awdx2r6jkvpi5x3bz8ghwatj6ktxfa057zaiaj

30 Mar 23

The present disclosure provides the use of a polyether compound.

Noriaki NISHIDA

Filed: 2 Feb 21

Utility

of07ti2 0xjxu3sojnxk037tape2n4z33fv02pq84jhladmalq1jk6l7r2

26 Jan 23

Tomoyo MIYABE, Shinnosuke MACHIDA, Yuka OBA

Filed: 3 Jul 20

Utility

t632dqmoc fmoe1omvstycn35yjw6ny9pe0jw

24 Nov 22

This disclosure provides a means for treating dry eye.

Takeshi TARUI, Shinya KOBAYASHI

Filed: 2 Oct 20

Utility

dd2lqym4f4vqzmgeedt6cfh3cj3gvhseapijybs4hfnrzvtmtbt

24 Nov 22

The present disclosure provides a novel use of nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR).

Masao Doi, Takeshi Nakajima, Mamiko Machida

Filed: 24 Jun 20

Utility

bw1hdysgyocl 1prbqya

22 Sep 22

The present invention provides a treatment drug or prophylactic drug for diseases, disorders, or conditions related to endoplasmic reticulum (ER) stress.

Noriko KOIZUMI, Naoki OKUMURA, Shigeru KINOSHITA

Filed: 3 Jun 22

Utility

7uae9k0zjyqsyfvn0fctqqteyrechnrz ozrds0wq7f0g41tpoe0co3g7ql

14 Jul 22

The present disclosure provides a marker that shows a relationship with changes in the nerve density and morphology in the cornea.

Jun SHIMAZAKI

Filed: 24 Apr 20

Utility

a1ikbhfm e7imxisi6jq2v

30 Jun 22

The purpose of the present invention is to provide a composition for preventing or treating neurotrophic keratitis.

Takeshi NAKAJIMA, Mamiko MACHIDA, Shuhei YAMADA

Filed: 14 May 20

Utility

0v7sf1asxxm hpqv304gqb444jzw2f3bxp9x6kcut1cdb8

11 Nov 21

The present invention relates to a retinal ganglion cell death suppressor comprising a BMPR signal transduction inhibitor, a drug comprising a BMPR signal transduction inhibitor for protecting retinal neurons, and a pharmaceutical composition using these for preventing or treating a disease involving retinal ganglion cell death, such as glaucoma, diabetic retinopathy and retinal vascular occlusion.

Yayoi KISHIMOTO, Chiho YABUTA

Filed: 28 Oct 19

Utility

zf0vp8y1aadub0cqdb1d7dg6npm1xdg7hcyn2

2 Sep 21

The objective of the present invention is to provide a hydrogel having a favorable shape stability not only after releasing an anionic drug contained but also in the process of releasing such an anionic drug, compared with the conventional techniques; and an anionic drug-containing ophthalmic device obtained by applying the hydrogel.

Yuki ITO, Yasuka WATANABE, Sho KODA, Toru MATSUNAGA, Takao SATO

Filed: 25 Jun 19

Utility

vjasqek4z6utxji76mh1

18 Mar 21

The present disclosure provides a composition for treating or preventing symptoms, disorders, or diseases of the corneal endothelium.

Noriko KOIZUMI, Naoki OKUMURA, Mayumi YAMAMOTO

Filed: 13 Dec 18

Utility

q5frkv339 nyzafqu1xlhk1t8q

4 Nov 20

The purpose of the present invention is to provide a PACAP peptide having increased stability.

Shinnosuke MACHIDA, Takeshi NAKAJIMA

Filed: 13 Nov 18

Utility

fc6s9fadatshvvh ynvk

23 Sep 20

The purpose of the present invention is to provide a peptide which has a neuroprotective action, a neuroprotective drug and neuropathic treatment containing said peptide, and a preventive or alleviative pharmaceutical composition.

Takeshi NAKAJIMA, Mamiko MACHIDA, Yujiro HAYASHI

Filed: 29 Mar 17

Utility

qvij0fa3z9vhdr36v4cj1vnq3j7n5di1m3wz8ch0xd8n1semf

26 Aug 20

Noriyuki Azuma, Taku Tanaka, Tadashi Yokoi

Filed: 2 Mar 20